New psychoactive substances (NPSs), also known as "designer drugs," present a rapidly evolving challenge in the global drug landscape. They are designed to mimic traditional illicit drugs while evading existing regulations, encompassing synthetic cannabinoids, cathinones, hallucinogens, and
No takes yet. Share an insight, caveat, or question.
Marco Pistis (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: